Pms30 - Cost Analysis for Different Anti-Rheumatoid Biological Treatments After Failure of Conventional Dmards in Patients With Moderate to Severe Rheumatoid Arthritis in the Kingdom of Saudi Arabia
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1744
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV